B Cell Lymphoma
Conference Coverage
Chemo-free Smart Start regimen looks promising in poor-prognosis DLBCL
CHICAGO – There was “oohing and aahing” over results showing high response and survival rates for combined rituximab, lenalidomide, and ibrutinib...
Conference Coverage
Fixed-duration venetoclax-obinutuzumab superior to standard CLL therapy
CHICAGO – The immediately practice changing study offers a time-limited frontline option, one expert reported.
News
Venetoclax plus ibrutinib appears to suit elderly and high-risk patients with CLL
The combination of venetoclax and ibrutinib outperformed previous reports of either of the two agents alone.
News
FDA approves lenalidomide/rituximab for previously treated FL, MZL
The approval is based on results from the phase 3 AUGMENT trial, which compared the combination treatment with placebo in previously treated...
News
Genetic analysis identifies prognostic markers in CLL
A single 11q22 deletion, lacking an ATM mutation on the other allele, had the shortest progression-free survival among patients with CLL who were...
News
CD23 expression linked to improved survival in MCL
Researchers found that mantle cell lymphoma cases that were CD23 positive had a higher frequency of leukemic nonnodal presentation and CD200...
News
Trial follow-up spotlights survival gains in follicular lymphoma
The 13-year update to the GITMO-IIL trial showed the important role of complete remission in prolonged survival. This is the longest follow-up...
News
FDA approves venetoclax/obinutuzumab combo for CLL
Venetoclax/obinutuzumab was compared with venetoclax/chlorambucil in the CLL14 study and showed superior progression-free survival in previously...
News
Inhibitor may overcome ibrutinib resistance in MCL
The inhibitor, IACS-010759, decreased tumor growth and prolonged survival in mouse models of ibrutinib-resistant lymphoma.
News
Idelalisib shows long-term safety, efficacy for relapsed CLL
The long-term data confirm that the addition of idelalisib to rituximab significantly improves outcomes for patients with relapsed CLL. However,...